Structure Therapeutics Inc. Sponsored ADR (GPCR)
(Delayed Data from NSDQ)
$16.78 USD
-0.81 (-4.60%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $16.76 -0.02 (-0.12%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
GPCR 16.78 -0.81(-4.60%)
Will GPCR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GPCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GPCR
LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback
GPCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for October 23rd
Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect?
NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise
Other News for GPCR
Structure Therapeutics (GPCR) Gains Analyst Support with Buy Rating
Structure Therapeutics initiated with bullish view at Clear Street, here's why
Goldman Sachs Initiates Coverage on Structure Therapeutics (GPCR) | GPCR Stock News
Structure Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy from Guggenheim